ADCT_4C_TM.png
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024 16:05 ET | ADC Therapeutics SA
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...
22157.jpg
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
January 22, 2024 21:23 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
logo-header-min.png
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 11, 2023 07:00 ET | Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Global Oncology-Based In-Vivo CRO Market
Oncology Based In-Vivo CRO Industry Experiences Surge with Innovative Solutions: Global Market Report 2023 Explores Trends and Growth Factors
December 11, 2023 04:28 ET | Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global market for...
Kura Oncology Logo
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
December 08, 2023 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
logo-header-min.png
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 17:00 ET | Marker Therapeutics
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...
ADCT_4C_TM.png
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023 10:10 ET | ADC Therapeutics SA
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated...
Global Leukapheresis Market
Leukapheresis Market Research Report 2023 - Global Opportunity/Analysis to 2028
September 25, 2023 10:33 ET | Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...
Emergen logo.png
Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
September 14, 2023 09:51 ET | Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...